ENGLEWOOD, CO / ACCESSWIRE / October 6, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs today reported financial results for its fiscal fourth quarter 2020, for the three month period ending June 30, 2020.
Fourth Quarter Fiscal 2020 Financial Highlights
Commenting on the fourth quarter of fiscal 2020, Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated "Revenue increased exponentially in Q4 2020, to $14.9 million, compared to $1.7 million for Q4 2019. It is important to note that this was the first full quarter of revenue from the combined Aytu and Innovus businesses, along with the Cerecor assets. Turning to the bottom line, adjusted EBITDA loss was reduced to just $1.7 million for Q4 2020, compared to a $3.7 million adjusted EBITDA loss for Q4 2019. On the balance sheet, with approximately $48.3 million in cash, cash equivalents and restricted cash after paying $15 million to fully extinguish the Deerfield balloon payment previously due January 2021, we have less than $1 million of debt, and at current spending levels, we believe we have sufficient runway to reach profitability."
Mr. Disbrow continued, "Taking a closer look at the top line, both of our revenue streams, from the Consumer Health and Rx segments, performed well. On the Consumer Health side, we generated $6.9 million in revenue, an increase compared to Q3. Contributing to those results was organic growth within our core Consumer Health product lines of diabetes care, sexual wellness and bladder health. Additionally, we strengthened our e-commerce business for Consumer Health. Furthermore, our newly launched Consumer Health product, Regoxidine, an over-the-counter foam formulation of minoxidil for hair regrowth, is on track to contribute revenue in excess of seven figures in its first twelve months from launch."
Mr. Disbrow added, "On the Rx side, revenue was $7.9 million, a significant increase compared to Q3. Contributing to Rx revenue was solid contribution from the pediatric franchise. Additional value was created with Natesto gaining preferred status on Express Scripts' national formulary and the Natesto spermatogenesis study results published in the Journal of Urology, both of which we expect to drive prescription growth in the coming quarters. Organic Rx growth was fueled by a relatively balanced contribution across our key products and improved sales execution. Despite the impact COVID has had on physician office access, Q4 represented a record revenue quarter for our Rx business and significant growth over the previous quarters. This is a strong statement about our field execution and clinical value of our products, and I'm pleased to see our call levels now picking back up to near normal in the current quarter to further drive prescription growth."
Mr. Disbrow concluded, "At $14.9 million in record quarterly revenue, with a narrowed Adjusted EBITDA loss, $48.3 million of cash, cash equivalents and restricted cash on the balance sheet, the addition of the Healight opportunity for COVID-19 and future potential non-COVID-19 applications, and our addition to the Russell 2000, we have strong momentum to grow shareholder value in fiscal 2021 and onward."
Conference Call Information
The company will host a live conference call at 4:30 p.m. ET today. The conference call can be accessed by dialing either:
877-407-9124 (toll-free)
201-689-8584 (international)
The webcast will be accessible live at https://www.webcaster4.com/Webcast/Page/2142/37506 and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.
A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 37506.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The recently acquired Pediatric Portfolio includes (i) Cefaclor, a second-generation cephalosporin antibiotic suspension; (ii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid test. This antibody test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. Aytu has also licensed the Healight Platform Technology. Healight is a pre-clinical investigational device being studied as a potential treatment for COVID-19 in severely ill, intubated patients and potentially other respiratory illnesses.
Aytu also operates a consumer health subsidiary, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company licensing, developing, and commercializing safe and effective consumer healthcare products designed to improve health and vitality. Innovus commercializes over twenty consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market and other conditions, our ability to successfully commercialize Healight Platform Technology, our ability to obtain FDA approval for the Healight Platform Technology, the effectiveness of the Healight Platform Technology in treating patients with COVID-19 or other illnesses, our ability to adequately protect the intellectual property associated with the Healight Platform Technology, regulatory delays, the reliability of the Healight Platform Technology in killing viruses and bacteria, market acceptance of UV based medical devices, the regulatory and commercial risks associated with introducing the COVID-19 rapid tests, any delays in shipment that may impact our ability to distribute the COVID-19 rapid tests, any reputational harm we may incur if there are delays in receiving the shipment of the COVID-19 rapid tests, our ability to enforce the exclusivity provisions of the distribution agreements, the reliability of serological testing in detecting COVID-19, shipping delays and their impact on our ability to introduce the COVID-19 rapid tests, the ability of the COVID-19 rapid tests to accurately and reliably test for COVID-19, the manufacturers of the COVID-19 rapid tests' ability to manufacture such testing kits on a high volume scale, manufacturing problems or delays related to the COVID-19 rapid tests, our ability to satisfy any labelling conditions or other FDA or other regulatory conditions to sell the COVID-19 rapid test kits, the demand or lack thereof for the COVID-19 rapid test kits, our ability to obtain additional COVID-19 rapid tests to meet demand, our ability to secure additional tests if the manufacturers of the COVID-19 rapid tests are unable to meet demand, the effects of the business combination of Aytu and the Pediatric Portfolio and the recently completed merger ("Merger") with Innovus Pharmaceuticals, including the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Pediatric Portfolio, the ultimate timing, outcome and results of integrating the operations the Pediatric Portfolio and Innovus with Aytu's existing operations, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors for our prescription products, the potential future commercialization.
Contact for Media and Investors:
James CarbonaraHayden IR(646) 755-7412james@haydenir.com
Non-GAAP Financial Information
This press release contains a financial measure that does not comply with U.S. generally accepted accounting principles (GAAP), Non-GAAP Adjusted EBITDA. Non-GAAP Adjusted EBITDA excludes (i) amortization, (ii) depreciation, (iii) stock-based compensation, (iv) other expenses comprising net interest expense, (v) non-cash gains and/or losses recognized in the quarter or year due to changes in the fair value of certain of Aytu's financial liabilities, such as contingent consideration, derivative warrant liability, or certain exchanges of debt, (vi) bad debt expense, (vii) impairment of certain long-lived assets; (viii) one-time transaction costs and (ix) costs associated with the Company's Healight technology. Management believes these measures are useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. In addition, Aytu believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Aytu's operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Statements of Operations
(Unaudited)
Three Months Ended June 30,
Revenues
Product revenue, net
License revenue, net
Total product revenue
Operating expenses
Cost of sales
Research and development
Selling, general and administrative
Selling, general and administrative - related party
Impairment of intangible assets
Amortization of intangible assets
Total operating expenses
Loss from operations
Other (expense) income
Other (expense), net
(Loss) / gain from change in fair value of contingent consideration
(Loss) on extinguishment of debt
Gain from warrant derivative liability
Total other (expense) income
Net loss
Weighted average number of shares outstanding ofcommon shares outstanding
Basic and diluted net loss per common share
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Balance Sheets
Assets
Current assets
Cash and cash equivalents
Restricted cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other
Other current assets
Total current assets
Fixed assets, net
Right-of-use asset
Licensed assets, net
Patents and tradenames, net
Product technology rights, net
Deposits
Goodwill
Total long-term assets
Total assets
AYTU BIOSCIENCE, INC. AND SUBSIDIARIESConsolidated Balance Sheets, Cont'd
Liabilities
Current liabilities
Accounts payable and other
Accrued liabilities
Accrued compensation
Debt
Contract liability
Current lease liability
Current portion of fixed payment arrangements
Current portion of CVR liabilities
Current portion of contingent consideration
Total current liabilities
Long-term contingent consideration, net of current portion
Long-term lease liability, net of current portion
Long-term fixed payment arrangements, net of current portion
Long-term CVR liabilities, net of current portion
Warrant derivative liability
Total liabilities
Go here to read the rest:
Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year - BioSpace
- Healthy Men: What women need to know about men's health - Greater Milwaukee Today - November 20th, 2020
- 24 Ways to Increase Penis Sensitivity: Tips, Techniques, and More - Healthline - October 18th, 2020
- Centrapeak Testosterone Booster Review: Is it Better than Others on the Market? - generationiron.com - October 18th, 2020
- Erectile Dysfunction: A Look at the Most Common Causes - Feed Leader - October 10th, 2020
- Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020 - Yahoo Finance - October 6th, 2020
- Whats Causing My Low Testosterone? - September 29th, 2020
- Indianapolis Low T Center & Men's Clinic | Sleep Apnea ... - September 29th, 2020
- Could This Device Help Save Covid-19 Patients Before the ICU? - Houstonia Magazine - September 6th, 2020
- Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study - Yahoo Finance - August 17th, 2020
- How can you actively boost your low libido? - Big Think - August 11th, 2020
- Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration - BioSpace - July 30th, 2020
- New Osteoporosis Recommendations From AACE Help Therapy Selection - Medscape - July 25th, 2020
- Hormone therapy no cure-all for 'low T' in ageing men - Health24 - July 20th, 2020
- Strain engineering of the magnetic multipole moments and anomalous Hall effect in pyrochlore iridate thin films - Science Advances - July 20th, 2020
- Does Low Testosterone Cause Night Sweats? - July 7th, 2020
- Treating low testosterone levels - Harvard Health - July 7th, 2020
- Some people who experienced no coronavirus symptoms may now be immune to Covid-19 - here's what the study says - Derry Journal - July 4th, 2020
- AGING: Hormone therapy no cure-all for low T in men - Palm Beach Post - July 2nd, 2020
- COVID 19 Effect on Low T Therapy Market: an Increase in Technology Development Will Heighten Growth of Key Players: AbbVie, Endo International, Eli... - June 23rd, 2020
- Freddy McConnell Gave Birth to His Son. Then His Life Changed. - Esquire - June 18th, 2020
- Low T Therapy Market: What Will Happen to Key Players After COVID 19 Ends: AbbVie, Endo International, Eli Lilly - Cole of Duty - June 9th, 2020
- Ego might drive men to testosterone therapy, but it helps with certain conditions - The Columbus Dispatch - June 8th, 2020
- What Are T-Cells and Can They Protect You from COVID-19? - Labmate Online - June 8th, 2020
- Aytu BioScience to Report Fiscal Q3 FY 2020 Results and Business Update - Yahoo Finance - May 7th, 2020
- COVID-19: T cells offer clues to the potential power of Roche's Actemra - FierceBiotech - May 6th, 2020
- Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly - 3rd... - May 6th, 2020
- New clues on how to treat COVID-19 from T cell counts - The Nation - May 3rd, 2020
- Aytu BioScience Signs Development Agreement with Sterling Medical Devices to Advance the Development of Healight as a Potential Coronavirus Treatment... - April 29th, 2020
- Low T Center Is Committed To Meeting The Needs Of Colorado Patients During The COVID-19 Emergency - P&T Community - April 20th, 2020
- Aytu BioScience Announces Positive Results from an Independently Conducted Clinical Study of the Company's Licensed COVID-19 IgG/IgM Point-of-Care... - April 17th, 2020
- The testosterone myth - The Week Magazine - April 12th, 2020
- Low T Therapy Market Industry Analysis, Size, Share, Growth, Trends And Forecast 2020 2024 - Monroe Scoop - March 26th, 2020
- Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care... - March 23rd, 2020
- No, not everything about mens sexual behaviour can be explained by testosterone - Scroll.in - March 23rd, 2020
- Letters to the editor - Boston Herald - March 9th, 2020
- Low Testosterone - Symptoms & Treatment | Everyday Health - March 6th, 2020
- Lost revenue from low T fares must be recouped - Boston Herald - March 1st, 2020
- Indiana Regenerative Medicine Institute Offers Innovative Approaches in Regenerative Medicine, Hormone Replacement and Pain Management - Carmel... - March 1st, 2020
- Low Testosterone Causes | Everyday Health - February 24th, 2020
- Diagnosis, treatment and how to avoid osteoporosis - The Gazette - January 30th, 2020
- The Signs a Testosterone Booster is Needed - Science Times - January 22nd, 2020
- New Guideline for Testosterone Treatment in Men With 'Low T' - Medscape - January 9th, 2020
- John R. Hampton III, MD, is recognized by Continental Who's Who - PRNewswire - November 27th, 2019
- Expert Insights on Osteoporosis From the ACR/ARP 2019 Annual Meeting - Rheumatology Advisor - November 27th, 2019
- Low T Specialist - Dallas, TX & Frisco, TX: Men's T-Clinic ... - October 5th, 2019
- Does Insurance Cover Low T Treatment - Mantality Health - October 5th, 2019
- Low Testosterone Therapy (TRT) and Treatment from Low T Center - September 27th, 2019
- Low T Center, 549 East County Line Road, Building 4 Suite D ... - March 31st, 2019
- Low T Symptoms | Low Testosterone | Signs of Low T - March 12th, 2019
- Low T Treatment in Texas & Illinois | SynergenX Health ... - February 18th, 2019
- The Lowdown on Low-T - Discover Health - Rush University ... - February 18th, 2019
- The Low T Scam? - Testosterone Centers of Texas - Low T ... - February 18th, 2019
- Low T 99 - Testosterone Therapy: Bellevue, Seattle, Tacoma ... - December 31st, 2018
- Men, Low T, and the Facts | Lifespan - October 1st, 2018
- Denver Low T Medical Clinic and Testosterone Therapy Center - August 6th, 2018
- You've Heard About "Low T" But What About "Low E"? - April 23rd, 2018
- Low T 99 - 10 Photos - Health & Medical - 1239 120th Ave NE ... - April 23rd, 2018
- Low Testosterone Treatment - Carolina Men's Clinic - April 23rd, 2018
- Low T-Helper (CD4) Cell Level - Symptoms and Diagnosis - March 2nd, 2018
- ED Clinic Nashville TN, Erectile Dysfunction Treatment, Low T - February 10th, 2018
- Low-Testosterone (Low-T) - Controversy Over ... - AARP - January 11th, 2018
- Low testosterone symptoms | Effects of low testosterone - January 11th, 2018
- About Low Testosterone | Low T Center - December 29th, 2017
- Low Testosterone Replacement Therapy | Low T ... - Men's T Clinic - November 12th, 2017
- low t | eBay - November 12th, 2017
- Low Testosterone (Low T) Treatments - onhealth.com - November 2nd, 2017
- Low-T (Low Testosterone) Quiz: Symptoms, Signs & Treatment - October 22nd, 2017
- Erectile Dysfunction/Low T Men's Health Georgia - September 4th, 2017
- 10 easy ways to transform old band T-shirts into something new - Alternative Press - August 30th, 2017
- AbbVie Hit With $150 Million Loss in Low-T Cardiac Trial - Lexology (registration) - August 19th, 2017
- Low T Center returning to sponsor Sorenson - ESPN - August 18th, 2017
- Older men with 'low T' can improve their sex lives with testosterone therapy, study says - Men's Fitness - August 18th, 2017
- Center for Men | Tulsa Men's Clinic | Tulsa Low T - August 17th, 2017
- `Make Men Great Again' Speakers Bash Trans People While Pumping Up America's Girly Men - Southern Poverty Law Center - August 10th, 2017
- Doctors Address Low Testosterone Ads - CBS St. Louis - August 9th, 2017
- Low T - Testosterone Replacement Therapy - Ehormones - August 2nd, 2017
- What does a low T cell count mean? DoctorNDTV Queries - August 2nd, 2017
- Column: Testosterone treatment reserved for men with symptoms ... - The Daily Courier - July 5th, 2017
- Testosterone treatment reserved for men with symptoms - Sarasota Herald-Tribune - July 5th, 2017
- Low T Trial: Testosterone Gel Increases Plaque in Arteries - DrugWatch.com - June 2nd, 2017